Leukotrap Wb System - Cp2d Solution
NDC Package 87069-126-63
Package Information
Leukotrap Wb System - Cp2d (cp2s/as-3 - anticoagulant and additive system) solution is a human prescription drug administered via intravenous route. This formulation utilizes a solution delivery system. Marketed by Gvs Tm Inc, this product is identified by NDC 87069-126 and is authorized under FDA application BN820915.
Identification & Billing
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 87069 - Gvs Tm Inc
- 87069-126 - Leukotrap Wb System - Cp2d
- 87069-126-63 - 6 POUCH in 1 CARTON / 3 BAG in 1 POUCH / 70 mL in 1 BAG
- 87069-126 - Leukotrap Wb System - Cp2d
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (87069-126). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 87069-126-63 identifies a specific commercial package of 6 pouch in 1 carton / 3 bag in 1 pouch / 70 ml in 1 bag of Leukotrap Wb System - Cp2d, a human prescription drug labeled by Gvs Tm Inc. This solution is formulated for intravenous use and contains dextrose, unspecified form as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gvs Tm Inc on June 23, 2026. The current certification is valid through December 31, 2027.
How is this Gvs Tm Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 87069012663. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.